Endothelin receptor antagonism: What does the future hold?

Hypertension

Volumn 52, Issue 3, 2008, Pages 460-461

  Sica, Domenic A ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ATRASENTAN; BOSENTAN; DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ENDOTHELIN RECEPTOR;

ANGIOCARDIOGRAPHY; AORTA PRESSORECEPTOR; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE REGULATION; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DIZZINESS; DRUG INDUCED HEADACHE; FIBROGENESIS; FLUID BALANCE; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY; KIDNEY BLOOD FLOW; MONOTHERAPY; NOSE CONGESTION; NOTE; OXIDATIVE STRESS; PATHOGENESIS; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECEPTOR BINDING; RECEPTOR BLOCKING; RISK BENEFIT ANALYSIS; SODIUM BALANCE; TREATMENT DURATION; UPREGULATION; VASOCONSTRICTION; DRUG ANTAGONISM; DRUG DESIGN;

ANTIHYPERTENSIVE AGENTS; DRUG DESIGN; HUMANS; HYPERTENSION; RECEPTORS, ENDOTHELIN;

EID: 52049107852     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.117226     Document Type: Note

References (9)

1. Kirkby NS, Hadoke PwF, Bagnall AJ, Webb DJ. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol. 2008;153:1105-1119.
2. Dhaun N, Pollock DM, Goddard J, Webb DJ. Selective and mixed endo-thelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci. 2007;28:573-579.
3. Feldstein C, Romero C. Role of endothelins in hypertension. Amer J Therapeutics. 2007;14:147-153.
4. Wilkes BM, Ruston AS, Mento P, Girardi E, Hart D, Vander Molen M, Barnett R, Nord EP. Characterization of endothelin I receptor and signal transduction mechanism in rat medullary interstitital cells. Am J Physiol Renal Physiol. 1991;260:F579-F589.
5. Bousette N, Giaid A. Endothelin-1 in atherosclerosis and other vascu-lopathies. Can J Physiol Pharmacol. 2003;81:578-587.
6. Raichlin E, Prasad A, Mathew V, Kent B, Holmes DR Jr, Pumper GM, Nelson RE, Lerman LO, Lerman A. Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension. 2008;52:522-528.
7. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med. 1998;338:784-790.
8. Nakov R, Pfarr E, Eberle S. Darusentan: an effective endothelin A receptor antagonist for treatment of hypertension. Am J Hypertens. 2002;15: 583-589.
9. Epstein BJ. Efficacy and safety of darusentan: a novel endothelin receptor antagonist. Ann Pharmacother. In press.